Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1301-1320 of 1,743 trials

Kidney Transplant: IVIG for BKV Prevention

We are studying whether intravenous immunoglobulins can help prevent BKV viremia in kidney transplant recipients with low antibody levels. This research aims to improve outcomes for patients at risk of BKV-related complications.

Kidney Transplant and BKV Infection>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesNephrology

Ewing Sarcoma: Dinutuximab Beta with Chemotherapy

We are studying a new treatment combining dinutuximab beta with standard chemotherapy for patients with GD2-positive Ewing sarcoma. The goal is to find the best dose and assess how well it works in improving patient outcomes.

Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Fecal Incontinence: Botulinum Toxin Injections

We are studying how botulinum toxin injections may improve rectal movement in patients with fecal incontinence. The trial will also look at the treatment's effectiveness, quality of life, and tolerance after one month.

Fecal Incontinence>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Acute Myeloid Leukemia: Venetoclax and Azacitidine Study

We are comparing a new treatment combination with standard chemotherapy for patients with newly diagnosed acute myeloid leukemia and NPM1 mutations. The goal is to see if this new approach is more effective and easier to tolerate.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Grass Allergy: Vitamin D Enhanced Immunotherapy

We are studying whether combining intralymphatic immunotherapy with vitamin D helps improve allergy symptoms in people with moderate to severe grass allergies during pollen season.

Allergic Rhinitis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesAllergology

Filgrastim for Severe Bullous Drug Eruptions

We are studying whether Filgrastim can help patients with severe drug reactions like Stevens-Johnson syndrome. The goal is to see if it slows disease progression and improves recovery compared to standard treatment alone.

Stevens Johnson SyndromeLyell Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Multiple Myeloma: New CAR-T Cell Therapy Study

We are testing a new CAR-T cell therapy for adults with relapsed or refractory multiple myeloma who have been treated with lenalidomide. The goal is to see if it works better than standard treatments currently available.

Relapsed/Refractory Multiple Myeloma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Solid Tumors: BGB-58067 Study

We are investigating a new treatment for patients with advanced solid tumors to see how safe it is and how well it works. This study will help us understand its effects on tumor growth.

Advanced Solid Tumors with MTAP DeletionNon-Small Cell Lung CancerCholangiocarcinoma>2 yearsSafety phase (I)Oncology

Ovarian Cancer: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with small cell ovarian carcinoma. The goal is to see how well this combination works and to evaluate its safety.

Ovarian Small Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oral Arsenic for Low-Risk Myelodysplastic Syndromes

We are studying whether oral arsenic can help patients with low-risk myelodysplastic syndromes who haven't responded to other treatments. The trial aims to assess its safety and effectiveness over 12 weeks.

Low-Risk Myelodysplastic Syndromes>2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

S-ketamine for Severe Acute Brain Injury

We are studying whether S-ketamine can help patients with severe acute brain injuries who have ongoing brain activity issues. The trial also looks at the safety of this treatment and its effects on recovery over six months.

Brain Hemorrhage and Injury>2 yearsMonitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Multiple Myeloma: JNJ-79635322 Treatment Study

We are exploring a new drug combined with existing therapies for patients with multiple myeloma. The goal is to see if this combination improves treatment outcomes.

Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Rhizarthrosis: Autologous Stromal Vascular Fraction Injection

We are studying the safety and effects of an injection using your own stem cells for treating rhizarthrosis. This trial will help us understand its impact on pain and joint function over several months.

Rhizarthrosis (Thumb Arthritis)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOrthopedics and TraumatologyRheumatology

CAR-T Cell Therapy: Understanding Extracellular Vesicles

We are studying how extracellular vesicles change before and after CAR-T cell treatment in patients, especially those experiencing neurotoxicity. This research may help improve patient care and treatment outcomes.

CAR T-cell Therapy>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesOncology

Multiple Myeloma and Knee Surgery: Apixaban Study

We are comparing how the blood thinner Apixaban works in patients with newly diagnosed multiple myeloma and those undergoing knee replacement surgery. This study aims to understand its effects on blood clotting and how it behaves in the body.

Thromboembolism Prophylaxis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyHematologyOncology

ImmunoPet Imaging in Solid Cancers: 89Zr-DFO-REGN5054

We are studying a new imaging method for adults with solid cancers who are being treated with Cemiplimab. This research aims to understand how effectively this imaging can track treatment progress.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Heart Procedure: Single vs. Dual Antiplatelet Therapy

We are comparing a single medication to a combination of two medications for patients after a heart procedure. The goal is to see if the single medication is just as safe and effective while reducing bleeding risks.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Pneumococcal Vaccine Response in Patients Without a Spleen

We are studying how the timing of pneumococcal vaccination affects immune response in patients who have had their spleen removed. This research may help improve vaccination strategies for asplenic individuals.

Asplenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementAllergologyHematologyInfectious Diseases

Almagate for Heartburn in Pregnant Women

We are studying the safety of almagate for treating heartburn and reflux in pregnant women. The trial also examines how this treatment affects the health of the fetus and newborn.

Heartburn and Reflux>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics